February 7, 2019
LexaGene announces that its LX technology has successfully detected the presence of two different pathogens from a single clinical urine sample in some of the first samples tested in the Company’s recently initiated clinical study.
February 4, 2019
LexaGene announces that it has started a clinical study to collect data using its LX genetic analyzer technology. The study will include testing urine samples collected from dogs suspected of having a urinary tract infection (UTI).
January 22, 2019
LexaGene announces it has formed a scientific advisory board comprised of key opinion leaders in the company’s targeted markets, namely food safety, veterinary diagnostics, and open-access markets such as biodefense.
January 3, 2019
LexaGene was featured on ABC-affiliated television station WCVB Boston on a segment of ‘Cutting Edge’ on December 21, 2018.
December 10, 2018
LexaGene announces completion of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common pathogens responsible for the majority of all clinical canine UTI cases.
December 3, 2018
LexaGene recently had an Industry Engagement Meeting with the Department of Homeland Security (DHS) regarding the applications of the company’s technology for DHS’ program on Countering Weapons of Mass Destruction (CWMD).
November 28, 2018
LexaGene named one of the 10 Most Promising Food and Beverages Solution Providers in 2018 by CIOReview.
October 22, 2018
LexaGene successfully unveils LX2™ beta prototype design on October 20th, 2018 to an enthusiastic gathering of veterinary professionals at the American Association of Veterinary Laboratory Diagnosticians (AAVLD) conference.
October 9, 2018
LexaGene to unveil LX2™ Beta Prototype design for the veterinary market at an upcoming industry event.
September 4, 2018
LexaGene announces that company President, Daryl Rebeck, will present at two upcoming investor conferences that are taking place in September 2018
For Marketing inquiries, please email:
info@lexagene.com
800-215-1824